These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9035043)

  • 21. Drug interactions: perspectives of the Canadian Drugs Directorate.
    Jurima-Romet M
    Adv Pharmacol; 1997; 43():239-54. PubMed ID: 9342180
    [No Abstract]   [Full Text] [Related]  

  • 22. Chirality in new drug development. Clinical pharmacokinetic considerations.
    Nation RL
    Clin Pharmacokinet; 1994 Oct; 27(4):249-55. PubMed ID: 7834962
    [No Abstract]   [Full Text] [Related]  

  • 23. Adding pharmacogenetics to the clinical laboratory: narrow therapeutic index medications as a place to start.
    Bukaveckas BL
    Arch Pathol Lab Med; 2004 Dec; 128(12):1330-3. PubMed ID: 15578874
    [No Abstract]   [Full Text] [Related]  

  • 24. Therapeutic ineffectiveness: heads or tails?
    Figueras A; Pedrós C; Valsecia M; Laporte JR
    Drug Saf; 2002; 25(7):485-7. PubMed ID: 12093306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What is the true risk of a pharmacokinetic drug-drug interaction?
    Fuhr U
    Eur J Clin Pharmacol; 2007 Oct; 63(10):897-9. PubMed ID: 17684737
    [No Abstract]   [Full Text] [Related]  

  • 26. Microdosing for reduction of the time and resources for drug development.
    Sudo K
    Drug Metab Pharmacokinet; 2007 Oct; 22(5):327. PubMed ID: 17965515
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical pharmacology: special safety considerations in drug development and pharmacovigilance.
    Atuah KN; Hughes D; Pirmohamed M
    Drug Saf; 2004; 27(8):535-54. PubMed ID: 15154826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
    Johnson TN; Rostami-Hodjegan A
    Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Editorial. Bioactivation of drugs: enzymes, reactive metabolites and adverse reactions.
    Orhan H
    Curr Med Chem; 2015; 22(4):406-7. PubMed ID: 25515506
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug interactions: Proteins, pumps, and P-450s.
    Shapiro LE; Shear NH
    J Am Acad Dermatol; 2002 Oct; 47(4):467-84; quiz 485-8. PubMed ID: 12271287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolite identification and profiling in drug design: current practice and future directions.
    Zhang Z; Zhu M; Tang W
    Curr Pharm Des; 2009; 15(19):2220-35. PubMed ID: 19601824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosensor profiling of molecular interactions in pharmacology.
    Cooper MA
    Curr Opin Pharmacol; 2003 Oct; 3(5):557-62. PubMed ID: 14559103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and toxicokinetics of bio-pharmaceuticals: technical problems.
    Kawai M
    J Toxicol Sci; 1996 Dec; 21(5):535-7. PubMed ID: 9035067
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacokinetic drug-drug interactions in the intensive care unit - single-centre experience and literature review.
    Łój P; Olender A; Ślęzak W; Krzych ŁJ
    Anaesthesiol Intensive Ther; 2017; 49(4):259-267. PubMed ID: 29027654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A "White Knight" role for DMPK researchers in pharmaceutical discovery: maximization of biomarker and translational M&S activities.
    Teramura T
    Drug Metab Pharmacokinet; 2012; 27(4):365-7. PubMed ID: 23268314
    [No Abstract]   [Full Text] [Related]  

  • 36. [Drug-drug interactions. An update].
    Morales-Olivas FJ; Estañ L
    Med Clin (Barc); 2006 Jul; 127(7):269-75. PubMed ID: 16942732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic transformation of clinically used drugs to epoxides: new perspectives in drug-drug interactions.
    Oesch F
    Biochem Pharmacol; 1976 Sep; 25(17):1935-7. PubMed ID: 985529
    [No Abstract]   [Full Text] [Related]  

  • 38. Variations of pharmacokinetics of drugs in patients with cirrhosis.
    Pena MA; Horga JF; Zapater P
    Expert Rev Clin Pharmacol; 2016; 9(3):441-58. PubMed ID: 26696448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.
    Lee CA; O'Connor MA; Ritchie TK; Galetin A; Cook JA; Ragueneau-Majlessi I; Ellens H; Feng B; Taub ME; Paine MF; Polli JW; Ware JA; Zamek-Gliszczynski MJ
    Drug Metab Dispos; 2015 Apr; 43(4):490-509. PubMed ID: 25587128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Physiolgically-based pharmacokinetics:Theory and examples.].
    Ishimoto T; Kato Y
    Clin Calcium; 2016; 26(11):1529-1537. PubMed ID: 27777386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.